Publication Description

Publication Summary

This new Insight Pharma Report examines the science behind therapeutic RNAi (RNA interference) and miRNA (microRNA), technologies for design of therapeutic oligonucleotides that work via an RNAi or miRNA-modulating mechanism, technologies for design of delivery vehicles, and leading specialty companies in the therapeutic RNAi/miRNA industry sector.

The report also includes a discussion of the outlook for the therapeutic RNAi/miRNA industry sector, including strategic issues such as technological prematurity and the development of enabling technologies, the role of Big Pharma investment, and the impact of patent litigation and cross-licensing in shaping the RNAi/miRNA sector. It also includes a scenario for the development of RNAi and miRNA-based drugs. Also included are transcripts of interviews with five leaders of biotech companies in the RNAi/miRNA industry sector.

For more information on the report, or to order it, see the CHI Insight Pharma Reports website.


October 2010


RNAi Therapeutics: Second-Generation Candidates Build Momentum Report


Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.

*Report is available for single user, multi-user, single-site, multi-site or for global use.